Search

Displaying results 4581 - 4590 of 10000 in total
  1. Drug

    SC-236

    go.drugbank.com/drugs/DB14059
    Experimental

    SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374

  2. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products. … [A32825] Pyrithione derivatives, such as [DB06815] and sodium pyrithione, are widely used as cosmetic preservatives and as anti-dandruff agents in shampoos.

  3. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection.

  4. Drug

    Meclofenoxate

    go.drugbank.com/drugs/DB13758
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Fominoben

    go.drugbank.com/drugs/DB08968
    ApprovedWithdrawn

    Fominoben is an antitussive agent.

  6. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

  7. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  8. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  9. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  10. Drug

    Norelgestromin

    go.drugbank.com/drugs/DB06713
    ApprovedInvestigational

    Norelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816] … It is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.